Quest Diagnostics (DGX) depicts a bullish outlook with the
PE Ratio of 20.87 as of November 02, 2024. The company beat
Q3 earnings and revenue estimates, leading to upgraded guidance for the full year 2024. Despite the sell-off by
Cambiar Investors LLC and
Assenagon Asset Management S.A., DGX shares hit a 52-week high, indicating strong investor confidence. The company's strategic acquisitions, including those from
University Hospitals' Outreach Laboratory Services, LifeLabs, and Allina Health, position it for growth and expansion. The acquisitions specifically aim to accelerate the adoption of
AI and digital pathology in cancer diagnosis. In addition, the company's partnership with BD aims to develop companion
diagnostics for cancer and other diseases. A new deal inked to acquire Allina Health and the company's expansion into Canada with a nearly $1 billion LifeLabs deal underscore the company's aggressive growth strategy. DGX has also been recognized as
'Best Place to Work for Disability Inclusion' for the seventh consecutive year, underscoring their focus on diversity and equity. These milestones paint a positive outlook for the future of DGX.
Quest Diagnostics DGX News Analytics from Tue, 09 Jan 2024 08:00:00 GMT to Sat, 02 Nov 2024 12:44:23 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
